Aurum Biosciences
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Imaging Centre of Excellence Queen Eliza...Phone Number
+44 1415821212Website
www.aurumbiosciences.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Aurum Biosciences
Aurum Biosciences is a UK-based clinical stage biopharmaceutical company focused on developing novel oxygen carriers for therapeutic and diagnostic use, particularly targeting acute ischaemic stroke and related conditions. Their patented ABL-101 platform technology aims to address oxygen deprivation in stroke patients, which is critical for improving outcomes in time-sensitive situations. The company has made significant progress with its lead product, ABL-101, which has completed early phase 1 and 2a human studies and is set to enter phase 2 trials in 2026. Aurum's innovations also extend to applications in inflammation imaging, heart disease, cardiac arrest, oncology, spinal cord injury, and traumatic brain injury.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aurum Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aurum Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Aurum Biosciences recently announced quarterly report
Check if Aurum Biosciences has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Aurum Biosciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Aurum Biosciences is spiking on competitors!
Click to see if Aurum Biosciences had a recent Job posting/layoffs
Product Launch: Get notified when Aurum Biosciences launches new products
Funding: Get notified immidiatlly once Aurum Biosciences has new funding data
Recommended Actions
Reach out to Masked Content who joined Aurum Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Aurum Biosciences
Compare insights from companies similar to Aurum Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Aurum Biosciences
<$5M
11-50
Private
<$5M
2010
N/A
Company Profile Activity
Activity Insights
Aurum Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aurum Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aurum Biosciences.
Aurum Biosciences financials insights
Gather financial insights about Aurum Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$875K
Aurum Biosciences Tech Stack
A closer look at the technologies used by Aurum Biosciences
See more technologies
Aurum Biosciences News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aurum Biosciences
Sign Up For FreeTo access detailed company insights
Aurum Biosciences is a UK-based clinical stage biopharmaceutical company focused on developing novel oxygen carriers for therapeutic and diagnostic use, particularly targeting acute ischaemic stroke and related conditions. Their patented ABL-101 platform technology aims to address oxygen deprivation in stroke patients, which is critical for improvi... Read More
